Takeda Pharmaceutical Co. Ltd. investors were energized to see the detailed Phase II data results on the company’s oral TYK2 inhibitor in psoriasis, TAK-279, which appear to position Takeda as a strong competitor to Bristol Myers Squibb Company and the first-in-class entry Sotyktu (deucravacitinib) it launched in the US last year.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.
